Steve Burton
Chief Executive Officer
Andy Davies
Sales & Marketing Director
Marc Hummersone
Senior Director of Research & Development
Colin Grant
Director of Quality & Regulatory Affairs
David Franklin
Chief Financial Officer
Chris Brown
Operations Director
Debbie Buzzell
HR Director
Steve Burton
Chief Executive Officer

Dr. Steve Burton has over 32 years of experience in company management, business development and the development of separation products and processes for the purification of biopharmaceuticals. He has been instrumental in the development of Prometic’s purification products and technologies which are used extensively for commercial manufacture of recombinant and plasma-derived protein therapeutics. Under Dr Burton’s direction, Astrea Bioseparations has grown to become a leading company in its field with a reputation for innovative, high quality/high performance chromatography adsorbents.

Dr. Burton gained his Ph.D. at the University of Cambridge and worked for Delta Biotechnology  (now Albumedix) in the UK before joining Astrea Bioseparations in 1988 as Research and Development Manager. Dr Burton has held various positions within Astrea Bioseparations and is currently President of Astrea UK & Isle of Man based bioseparations subsidiary.

Andy Davies
Sales & Marketing Director

Andy is an Experienced Sales Director with over 25 years’ experience in the biotech and life sciences sectors, specialising in bioprocessing and bioseparation techniques with degree level Biochemistry from the University of West London. Having started his career working in a research and development laboratory, Andy progressed into consultative sales roles for capital high-tech equipment and strategic account management, leveraging his lab experience for large pharmaceutical companies such as GE.

Andy has been with Astrea Bioseparations (Astrea) for over 5 years with responsibilities covering the global sales and marketing of its products and services. Since joining Astrea, Andy has been instrumental in developing the product pipeline by successfully launching the ever-growing Evolve column range into Astrea’s offering

Marc Hummersone
Senior Director of Research & Development

Marc Hummersone has over 20 years of project and managerial roles in both big and small technology Companies, including industry leaders AstraZeneca, General Electric Healthcare & Cytiva. He has a wide experience base across a broad range of technologies including the development of novel chromatographic media for the purification of complex biological feeds streams and drug discovery and development. He was also a key contributor to the development of the Fibro chromatography family of products which resulted in the acquisition of Puridify, by GE Healthcare in 2017. Additionally, he was part of the management team who identified, and developed Lymparza, which is an approved drug for the treatment of BRCA-mutated advanced ovarian cancer and resulted in the acquisition of KuDOS Pharmaceuticals in 2005. He gained a PhD and Post Doctoral work in chemistry was focused on natural product total synthesis of complex natural products at University College, London.

Colin Grant
Director of Quality & Regulatory Affairs

Colin has over 20 years management experience in Quality and Regulatory Affairs within the Pharmaceutical and Biotech sector. Having begun his career within Quality Control in GSK he moved into other areas of compliance including Herbal, Small Molecule, ATMP and Human Tissue implementing and maintaining HTA and GMP licences in a number of sites using a ISO 9001 Quality Management System and associated certifications.

Colin joined Astrea Bioseparations in 2015 to implement and develop a Quality Management System that adheres to GMP for Active Substances, is compliant with ISO 9001:2015 and uses a Lean approach to manufacturing.

David Franklin
Chief Financial Officer

David is an experienced Chief Financial Officer who has worked in the Astrea Group in various roles since 2007. David joined the Company as UK Financial Controller after obtaining a Bachelor’s degree in Business Studies from the University of Nottingham and then going on to qualify with the Institute of Chartered Accountants in England and Wales within practice, gaining vital commercial and technical experience within multiple sectors. He then progressed to be Group Director of Financial Planning & Analysis, and Finance Director before moving into his current role in early 2020 as Chief Financial Officer.

David heads up the finance team in the UK, whilst working closely with the CEO and other management team members to provide a wealth of commercial and strategic insight and direction.

Chris Brown
Operations Director

Chris is an Experienced production manager with over 27 years’ experience in chemical and pharmaceutical manufacturing. Having started his career working in a research and development laboratory, Chris progressed into large scale manufacturing of fine chemicals and then into Pharmaceutical API manufacturing with Pfizer. He has a degree in Applied chemistry and is a Chartered Manager.

Chris has been with Astrea Bioseparations (Astrea) for over 6 years with responsibilities covering the manufacturing of mimetic adsorbents. Since joining Astrea, Chris has been instrumental in developing a 5-fold increase in manufacturing capacity to meet Astrea’s ambitious growth expectations.

Debbie Buzzell
HR Director

Debbie began her HR career working for the NHS, since this she has progressed to various HR leadership roles in technology, science and manufacturing – with over 25 years’ experience in these sectors. Debbie is a Fellow of the Chartered Institute of Personnel & Development and has a total of 40 years’ experience in HR.

Debbie started at Astrea Bioseparations in 2019 as Head of Human Resources before moving on to her current role of HR Director.